BLB(SZ:002286) Xin Lang Cai Jing·2025-09-24 02:12Company Overview - Baolingbao Bio-Technology Co., Ltd. is located in Dezhou, Shandong Province, and was established on October 16, 1997. The company was listed on August 28, 2009. Its main business involves the research, production, and sales of functional sugars [1][2]. Financial Performance - For the first half of 2025, Baolingbao achieved operating revenue of 1.399 billion yuan, representing a year-on-year growth of 18.02%. The net profit attributable to shareholders was 92.672 million yuan, reflecting a year-on-year increase of 33.66% [2]. - Since its A-share listing, Baolingbao has distributed a total of 309 million yuan in dividends, with 95.072 million yuan distributed over the past three years [3]. Stock Performance - As of September 24, Baolingbao's stock price increased by 2.20% to 9.77 yuan per share, with a total market capitalization of 3.714 billion yuan. The stock has seen a year-to-date increase of 33.47%, but has declined by 4.96% over the past five trading days, 16.85% over the past 20 days, and 23.73% over the past 60 days [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent occurrence on May 22, where it recorded a net buy of -50.8373 million yuan [1]. Shareholder Information - As of September 10, Baolingbao had 34,400 shareholders, a decrease of 6.59% from the previous period. The average number of circulating shares per shareholder increased by 7.06% to 10,739 shares [2]. Business Segments - The main revenue composition of Baolingbao includes: starch sugars and others (29.89%), sugar-reducing sweeteners (26.55%), feed and by-products (22.40%), probiotics (13.48%), dietary fiber (7.39%), and others (0.29%) [1]. Industry Classification - Baolingbao belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically under the subcategory of agricultural product processing, and is involved in various concept sectors including sugar substitutes, synthetic biology, biomedicine, small-cap stocks, and participation in the New Third Board [2].